AzTrials
AzTrials

Olfaction DisordersNCT04799977

COVID-19: Post-covid Olfactory Disorders Assessment

An observational study of Olfaction Disorders, run by Centre Hospitalier Universitaire de Nice at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Covid 19 cause an olfactory loss in more than 80% of cases. This loss most often regresses but leaves 20% of patients with an olfactory complaint, particularly with regard to the quality of daily life. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Olfaction Disorders
How many people
56 participants
Where
1 siteFrance
Study dates
1 Oct 2020to 1 Apr 2021
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: All adult patients who presented with anosmia during their COVID19 infection (proven by a PCR+ test) and presenting at the ENT department consultation in university hospital more than 6 weeks after the end of symptoms,

Who may be able to join

  • Adults patient,
  • anosmia during a COVID19 acute infection (PCR+) and persistant olfactive disoders at least 6 weeks after symptoms disappeared.

Who cannot join

  • preexisting smell loss.

Trial locations and contacts

1 site in 1 country.

France1 site
  • IUFC

    Nice, 06100

Other trials in France

About this study

Official title: Persistent Olfactory Loss After COVID-19 : Olfactive Disorder, Psychiatric and/or Cognitive Assessments With and Without a Treatment

Covid 19 cause an olfactory loss in more than 80% of cases. This loss most often regresses but leaves 20% of patients with an olfactory complaint, particularly with regard to the quality of daily life. The neuro-cognitive implications involved with COVID19 and the consequences of persistent olfactory loss remain unknown. The effectiveness of therapeutic management, in particular olfactory re-education, has not yet been clarified. Objectives are the assessment of patients olfactory disorders, psychiatrics and neurocognitives specificities after a COVID, before and after treatment or specific cares.

Medical subject headings
Olfaction Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT04799977
Study groupRoleWhat they receive
COVID19 infection with olfaction disorderPatients, ≥18 ans, who suffered from an olfaction disorder while going through a COVID19 infection
COVID19 infection without olfaction disorderPatients, ≥18 ans, who suffered from a COVID19 infection without any olfaction disorders

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Sniffin Stick Tests (score TDI)

    The subjective olfactory losses and recoveries are most often evaluated using the "Sniffin 'Sticks Test®", the current gold standard of objective olfactory tests allowing in a single examination to group together: the definition of an olfactory threshold, olfactory discrimination and olfactory identification in the form of an overall TDI score. Olfactory function using psychophysical tests before and after treatment or specific cares : Sniffin Stick Tests (score TDI). Results can classified patients in Anosmic (TDI<16,25), Hyposmic (16,25<TDI<30,75) and Normosmic (TDI>30,75). Higher score = better results. Minimal clinically important difference = 5,5.

    Measured: 12 months : Evalation at the beginning and the end.

Secondary outcomes (13)
  1. Hamilton Depression Rating Scale (HDRS)

    The HDRS is used to assess the severity and progression of a patient's depressive state during a structured interview. This is a hetero-questionnaire consisting of 21 items completed in a few minutes by the examiner after an interview of at least 30 minutes. Before and after treatment or specific cares. Min-Max = 10-21. 10 < score < 13 = lights depression symptoms; 14<score<17 = mild deppression symptoms; >18 = severe deppression symptoms ; Interrelationships assessment between psychophysical tests and theses results

    Measured: 12 months : Evaluation at the beginning and the end.

  2. Situational anxiety and anxiety trait inventory (STAI-Y)

    The STAI is a self-administered questionnaire comprising 40 items. This scale consists of 2 parts: one evaluating the anxiety-state (AE) which reflects the current emotional state and the other evaluating trait anxiety (AT) which reflects the usual emotional state. Before and after treatment or specific cares. Each score can vary from 20 to 80 with a "very high" (> 65), "high" (56-65), "average" (46-55), "low" (36-45) and "very low" (<or = 35). Interrelationships assessment between psychophysical tests and theses results

    Measured: 12 months : Evaluation at the beginning and the end.

  3. PTSD checklist for DSM-5 (PCL-5)

    The PCL-5 is a 20-item self-report that measures the 20 PTSD symptoms of DSM-5. The goals of PCL-5 are many, such as monitoring changes in symptoms during and after treatment, identifying individuals with PTSD, and making a provisional diagnosis of PTSD. Before and after treatment or specific cares. This self-rated scale scores each symptom from 0 to 4. Min-Max (better)=0-20. Interrelationships assessment between psychophysical tests and theses results.

    Measured: 12 months : Evaluation at the beginning and the end.

  4. GREMOTS

    GREMOTS is a speech assessment test for neurological pathologies. This battery of tests takes into account the latest scientific development in the field and evaluates the different psycholinguistic variables of language. It also aims to detect disorders from the early stage of the disease. It componed of differents subtypes. We used the denomination and verification tasks. Semantic verification task: Min-Max=0-18. The cut-off score is between 5 and 25 percentil (inferior to 10-14). Denomination task: Min-Max=0-36. The cut-off score is between 5 and 25 percentil (inferior to 31-34).

    Measured: 12 months : Evaluation at the beginning and the end.

  5. PPT

    The Pyramids and Palm Trees Test is a commonly used test of associative semanticknowledge comprising 52 items. In this test, participants are shown a stimulus (e.g., a pyramid) and asked to match it toeither of two images: A target (e.g., a palm tree) or a distracter (e.g., a fir tree). Subjects are required to use explicit semantic information of encyclopedic (e.g., pyramid: Palm tree vs. fir tree) or functional (e.g., wood: Saw vs. hammer) nature to select the correct match. Min-Max: 0-52. The 5% cut-off score corresponds to a Z-score of -1.65.

    Measured: 12 months : Evaluation at the beginning and the end.

  6. GROBER BUSCHKE

    Grober and Buschke's is a commonly used test assesses verbal memory and is made up of 16 items belonging to 16 different semantic categories. The indexed reminder makes it possible to check the efficiency of the encoding and to dissociate memory disorders according to their type. Min-Max: 0-48. The cut-off score is inferior to 25 percentil.

    Measured: 12 months : Evaluation at the beginning and the end.

  7. TAP (Test of Attentional Performance)

    The investigators used two tasks: the alertness task and the sustained attention task. In the alertness's task, reaction time is examined under two conditions. In the sustained attention task, a sequence of stimuli is presented on the monitor. The stimuli vary in a range of feature dimensions: colour, shape, size and filling. In order to adapt the difficulty of the task to the performance level of a subject, different levels of difficulty, that is, reactions to "shape" only or to "colour or shape", may be selected. Norms are betwaeen 19 and 89 for the alertness task and between 19 and 72 in sustained attention task.

    Measured: 12 months : Evaluation at the beginning and the end.

  8. TODA2 Olfactive Identification

    The olfactory test was developed by the CoBTeK laboratory. It's an electronic test with mobile application which is componed of two tasks: a treshold task and an identification task. This task assess more precisely odor identification disorders by presenting semantic distractors at the higer treshold level. Min-Max treshold score: 1-4. Min-Max identification score: 0-24

    Measured: 12 months : Evaluation at the beginning and the end.

  9. Snaith-HAmilton Pleasure Scale (SHAPS)

    The SHAPS is a 14-item self-administered questionnaire designed to assess a patient's hedonic capacity under different circumstances of daily life. Before and after treatment or specific cares. Min-Max = 0-14. Score >3 Anhédonic symptom; Interrelationships assessment between psychophysical tests and theses results

    Measured: 12 months : Evaluation at the beginning and the end.

  10. Inventory/Apathy Scale

    The principle of the Apathy Inventory (IA) is to obtain information on the presence of apathy in patients with neurological disorders. The investigators used the clinical version of the Apathy Inventory. It assess the 4 clinical dimensions: - Emotional blunting - Lack of initiative - Lack of interest- Social interactions. Score for each dimension: 0= no problem; 2= moderate problem; 4= major problem. Min-Max total score= 0-16..

    Measured: 12 months : Evaluation at the beginning and the end.

  11. Olfactory Quality of life assessment - Short Version of questionnaire of olfactory disorders

    Specific quality of life related to olfaction disorders concerning Social, eating, anxiety and daily annoyance related behaviors. Min-Max = 0-21, the higher is the score, the better is olfactory quality of life

    Measured: 12 months : Evaluation at the beginning and the end.

  12. General quality of life assessment (SF-36)

    General quality of life score. Two scores related to an aggregated physical score and a mental score. Normatives values are near 50 for both. Less than 45 is worst subdomain quality of life, better than 55 is better subdomain quality of life. MCID = 5

    Measured: 12 months : Evaluation at the beginning and the end.

  13. The French quality of life and diet scale (QV-AF)

    The QV-AF is a scale developed and validated in French to assess the quality of life in adults and in particular the relationship to diet. 4 subscales: diet / pleasure dimension, diet / relationship dimension, diet / psychology dimension, diet and physical condition dimension. Before and after treatment or specific cares. Min-Max (better)=0-400. Interrelationships assessment between psychophysical tests and theses results.

    Measured: 12 months : Evaluation at the beginning and the end.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Mar 2021
  2. Study start1 Oct 2020
  3. Primary completion1 Apr 2021
  4. Study completion1 Apr 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
56 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04799977
Sponsor's protocol ID
21IUFCcovid01
Status last verified
Apr 2021
First submitted
15 Feb 2021
Last updated
22 Apr 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Dumas LE, Vandersteen C, Metelkina-Fernandez V, Gros A, Auby P, Askenazy-Gittard F. Impact of post-COVID-19 olfactory disorders on quality of life, hedonic experiences and psychiatric dimensions in general population. BMC Psychiatry. 2024 Feb 8;24(1):111. doi: 10.1186/s12888-024-05538-0.

    PubMed 38331799

Questions about this trial

What is this clinical trial studying?

An observational study of Olfaction Disorders, run by Centre Hospitalier Universitaire de Nice at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Sniffin Stick Tests (score TDI) (time frame: 12 months : Evalation at the beginning and the end.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04799977, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Apr 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in